Scotiabank initiated coverage of Danaher with a rating of Sector Perform

Guggenheim initiated coverage of Danaher with a rating of Buy and set a new price target of $275.00

BofA Securities upgraded Danaher from Neutral to Buy and set a new price target of $290.00

Wolfe Research upgraded Danaher from Peer Perform to Outperform and set a new price target of $285.00

Stephens initiated coverage of Danaher with a rating of Overweight and set a new price target of $315.00

Wells Fargo initiated coverage of Danaher with a rating of Equal Weight and set a new price target of $280.00

Jefferies resumed coverage of Danaher with a rating of Buy and set a new price target of $295.00

HSBC Securities upgraded Danaher from Hold to Buy and set a new price target of $280.00

Barclays downgraded Danaher from Overweight to Equal Weight and set a new price target of $240.00

HSBC Securities initiated coverage of Danaher with a rating of Hold

New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif., Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative disease research. These assays are intended to assess p-Tau217, GFAP, NfL, and APOE ε4 biomarkers, which are emerging as the most important biomarkers in neurodegenerative diseases research, including interventional clinical trials. "Adv

WASHINGTON, Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year.Estimated non-GAAP core revenue for the fourth quarter of 2024 is expected to be essentially flat year-over-year, which would be above the Company's previously announced guidance of a low-single digit percent decline.As previously announced, Danaher will hol

Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions.Investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.WASHINGTON, Jan. 9, 2025 /PRNewswire/ -- Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced today that they have formed an investment partnership with Innovaccer Inc., a leading healthcare artificial intelligence (AI) company. Innovaccer has built a suite of software solutions designed to create a unified patient record to identify gaps in care and pati

WASHINGTON, Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025 at 11:15 a.m. PT. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most i

WASHINGTON, Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. Y

WASHINGTON, Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagno

WASHINGTON, Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Wednesday, December 4, 2024 at 3:25 p.m. ET. The event will be simultaneously webcast on www.danaher.com. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven

WASHINGTON, Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71.Revenues increased 3.0% year-over-year to $5.8 billion and non-GAAP core revenue increased 0.5%.Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.2 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Our team delivered strong third quarter resu

WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. Y

BREA, Calif. and TEL AVIV, Israel, Sept. 17, 2024 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio's X100 / X100HT with FF-BMA Application are CE-Marked. Bone marrow aspirate analysis is a vital procedure providing essential information for the assessment of various hematologic diseases.i By as

DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.   Ms. Sawyer Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair.  Rainer Blair com

Move reflects increasing investment in AI as driving force for innovation and productivity.Company will host Innovation Summit in December focused on AI in R&D.WASHINGTON, June 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role. Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danaher, said: "We are delighted to welcome Dr. Stumpe to our team. His extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting

New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract fundingNobel laureate Doudna and team to partner with Danaher to oversee center's translational and clinical researchWASHINGTON, Jan. 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) and the Innovative Genomics Institute (IGI) today launched a collaborative center to develop gene-editing therapies fo

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, the S&P MidCap 400 and the S&P SmallCap 600 indices: Veralto Corp. (NYSE:VLTO) will be added to the S&P 500 effective prior to the open of trading on Monday, October 2, replacing DXC Technology Co. (NYSE:DXC) which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Tuesday, October 3. DXC Technologies will replace Ebix Inc. (NASD: EBIX) in the S&P SmallCap 600 also effective prior to the open of trading on October 3. S&P 500 &100 constituent Danaher Corp. (NYSE:DHR) is spinning off Veralto in a transaction expected to be completed on October 2. Followin

Investments set foundation for global platform of laboratory-automation technologies serving environmental, agricultural and food-and-beverage applications Battery Ventures, a global, technology-focused investment firm, today announced the creation of a new laboratory-automation platform following recent acquisitions of three complementary companies: Skalar Analytical, PromoChrom Technologies and LCTech. Skalar Analytical, based in Breda, the Netherlands, manufactures a range of chemistry analyzers and laboratory-automation solutions for environmental and agricultural applications. Skalar serves as the foundation for the new platform, while PromoChrom—which is based in Richmond, British

WASHINGTON, June 29, 2022 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members. Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners. Mr. Dewan earned his B.S. in Engineering with a Certificate in Applied and Computational Mathematics from Princeton University. Steven M. Rales, Chai

CORALVILLE, Iowa, Sept. 1, 2021 /PRNewswire/ -- Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today that Demaris Mills has been appointed President of the Company, succeeding Trey Martin, who was promoted to a new position in Genomic Medicine within Danaher, IDT's parent company. The leadership transition comes at a time when IDT is growing its product solutions, expanding its global footprint, has a seasoned leadership team, and has the advantage of the Danaher Business System (DBS) culture. Mills has been with Danaher comp

WASHINGTON, Aug. 24, 2021 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced that, effective April 1, 2022, Georgeann F. Couchara will succeed Angela S. Lalor as Senior Vice President, Human Resources. At that time, Ms. Lalor will move to a part time, advisory role until her retirement in the first quarter of 2023. Ms. Couchara, currently Vice President, Talent for the Company, will join the Danaher Leadership Team and the Office of the Chief Executive, reporting to Rainer M. Blair, Danaher's President & Chief Executive Officer. Additionally, the Company announced that Christopher M. Bouda will succeed Robert S. Lutz as Chief Accounting Officer of Danaher, effect

WASHINGTON, May 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed A. Shane Sanders to its Board of Directors and to its Audit Committee. This addition expands the size of Danaher's Board from twelve to thirteen members. Mr. Sanders is currently Senior Vice President of Business Transformation at Verizon Communications Inc. (NYSE:VZ). Since joining Verizon in 1997, he has served in a series of progressively more responsible leadership positions including as Senior Vice President of Corporate Finance from 2015 to 2020. Prior to joining Verizon, Mr. Sanders served in various finance roles at Hallmark Cards, Inc. and Safelite Glass Corporation, and beg